MYCN (N-myc)
MYCN is a growth-driving gene that some neuroblastomas copy many times over; that amplification is one of the strongest signs the tumour is aggressive and sets the intensity of treatment.
Overview
MYCN encodes the N-myc transcription factor, a paralogue of MYC expressed in the developing neural crest. Amplification (many extra copies, detected by FISH) occurs in about 20 percent of neuroblastomas and places a child in the high-risk group of the INRG and COG classifications whatever the age or stage; it also defines a rare aggressive spinal ependymoma group and is amplified in some medulloblastomas and retinoblastomas. There is no approved MYCN-directed drug; the readout page carries the amplification rule and the risk groups that use it.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MYCN is a growth-driving gene that some neuroblastomas copy many times over; that amplification is one of the strongest signs the tumour is aggressive and sets the intensity of treatment.
- 1 · What it is
MYCN is a growth-driving gene that some neuroblastomas copy many times over; that amplification is one of the strongest signs the tumour is aggressive and sets the intensity of treatment.
- 2 · What goes wrong in cancer
N-myc dimerises with MAX and drives proliferation, ribosome biogenesis and metabolic programmes while repressing differentiation; amplified tumours depend on it and are being targeted indirectly through Aurora A, BET and CDK7 inhibitors.
- 3 · How drugs use it
No product in this corpus aims at MYCN (N-myc) yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
What a pathology or genomic report can say about this target, each with the thresholds approvals use.
Biology
N-myc dimerises with MAX and drives proliferation, ribosome biogenesis and metabolic programmes while repressing differentiation; amplified tumours depend on it and are being targeted indirectly through Aurora A, BET and CDK7 inhibitors.
- Neuroblastoma (amplified in about 20 percent)
- Spinal ependymoma, MYCN-amplified
- Medulloblastoma group 3
- Retinoblastoma
Latest papers
topQuery for this target: (TITLE:"MYCN" OR ABSTRACT:"MYCN" OR TITLE:"N-myc" OR ABSTRACT:"N-myc" OR TITLE:"NMYC" OR ABSTRACT:"NMYC" OR TITLE:"bHLHe37" OR ABSTRACT:"bHLHe37") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MYCN (N-myc), not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetHistone H3.3 (H3-3A)
Shares CIViC, IntOGen, Open Targets Platform and the tag biomarker-parent.
- TargetMGMT (O6-methylguanine-DNA methyltransferase)
Shares CIViC and the tag biomarker-parent.
- TargetKi-67 (MKI67)
Shares CIViC and the tag biomarker-parent.
- TargetPTEN
Shares CIViC, IntOGen, Open Targets Platform and the tag biomarker-parent.
- TermSegmental chromosomal aberrations and ploidy (neuroblastoma)
Shares MYCN amplification, MYCN amplification, FISH / ISH (in situ hybridisation), High-risk neuroblastoma.
- TargetETV4
Shares Neuroblastoma (paediatric), CIViC, IntOGen, Open Targets Platform.
- TreatmentEflornithine (DFMO)
Shares MYCN amplification, High-risk neuroblastoma, Neuroblastoma (paediatric).
- TargetMSI2
Shares Neuroblastoma (paediatric), IntOGen, Open Targets Platform.